Kaposi's sarcoma: a reevaluation
- PMID: 7541146
Kaposi's sarcoma: a reevaluation
Abstract
Kaposi's sarcoma (KS) is a multicentric neoplasia of microvascular origin arising during development of immunodeficiency in human immunodeficiency virus (HIV)-infected individuals. More than 130 patients with HIV-associated KS (98% male homosexuals; median age, 35 years) have been diagnosed at the Department of Dermatology, University Medical Center Steglitz, Berlin, during the years 1982-1992. Mucocutaneous and visceral involvement was a common finding in patients with HIV-associated KS, increasing from 39% at the first visit to 65% at the last observation. In 90% of the patients significant immunosuppression was found (75% had a CD4+ count < 200/mm3) at the time of first diagnosis. However, immunosuppression was not a prerequisite for the development of KS, since the tumor had been diagnosed before severe immunosuppression was present in about 10% of the patients. Significant prognostic predictors for the final outcome were: (a) the degree of immunosuppression, (b) the presence of mucosal and visceral manifestation, and (c) the past history of opportunistic infections. The median survival time was 28 months in KS patients with more than 300 CD4+ lymphocytes (n = 18), but only 14 months in immunosuppressed (less than 300 CD4+ lymphocytes) individuals with KS (n = 70). The median survival time in the entire group evaluated (n = 89 patients) was 17 months after first diagnosis. In 71 HIV-infected individuals who died at the Berlin Department during the last 8 years, disseminated KS was the major direct or indirect cause of death (49% of cases). Therapeutic benefit for KS patients was observed after long-term administration of recombinant interferon alpha (rIFN-alpha; 9-18 million IU s.c. every 2 days) alone or combined with antiretroviral drugs such as zidovudine over several months. Prolongation of survival was found after such treatment modalities in 30%-40% of treated patients. Bleomycin and vincristine and other systemically used cytostatics have also been applied with moderate results. The etiology of HIV-associated KS is still unknown and coinfection with herpes simplex virus (HSV), cytomegalovirus (CMV), or human papillomavirus (HPV) as well as certain growth-stimulating cytokines (transforming growth factors, TGF; tumor necrosis factor alpha, TNF-alpha; interleukin-6, IL-6; tat; vascular endothelial growth factors, VEGF; oncostatin M) produced by HIV-infected cells may be cofactors. Overall, KS was found to be a tumor with high malignant potential, and the median survival times were short.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Phase I/II trials of alpha-interferon alone or in combination with zidovudine as maintenance therapy following induction chemotherapy in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma.Semin Oncol. 1991 Oct;18(5 Suppl 7):53-7. Semin Oncol. 1991. PMID: 1719642 Clinical Trial.
-
[Disseminated mucocutaneous Kaposi sarcoma in AIDS. Clinical and therapeutic experiences in 13 patients].Hautarzt. 1987 May;38(5):286-94. Hautarzt. 1987. PMID: 3610636 German.
-
Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.Arch Intern Med. 1994 Mar 14;154(5):566-72. Arch Intern Med. 1994. PMID: 8122950
-
Overview of the management of AIDS-related Kaposi's sarcoma.Ann Pharmacother. 1996 Oct;30(10):1150-63. doi: 10.1177/106002809603001015. Ann Pharmacother. 1996. PMID: 8893123 Review.
-
Kaposi's sarcoma. An Update.Dermatol Surg. 1996 Mar;22(3):274-87. Dermatol Surg. 1996. PMID: 8599740 Review.
Cited by
-
Metastatic Kaposi's Sarcoma with Perirectal Involvement Diagnosed with Endoscopic Ultrasound-Guided EchoBrush Cytology Sampling.Case Rep Gastroenterol. 2011 May;5(2):416-21. doi: 10.1159/000330480. Epub 2011 Jul 22. Case Rep Gastroenterol. 2011. PMID: 21829398 Free PMC article.
-
Diagnosing HIV-related disease: using the CD4 count as a guide.J Gen Intern Med. 1998 Feb;13(2):131-6. doi: 10.1046/j.1525-1497.1998.00031.x. J Gen Intern Med. 1998. PMID: 9502375 Free PMC article. Review.
-
Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus.PLoS Pathog. 2010 Aug 12;6(8):e1001046. doi: 10.1371/journal.ppat.1001046. PLoS Pathog. 2010. PMID: 20730087 Free PMC article.
-
Human herpesvirus-8 in Kaposi's sarcoma of the conjunctiva in a patient with AIDS.Jpn J Ophthalmol. 2006 Jan-Feb;50(1):7-11. doi: 10.1007/s10384-005-0268-y. Jpn J Ophthalmol. 2006. PMID: 16453181
-
Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma.Med Microbiol Immunol. 2003 Aug;192(3):165-9. doi: 10.1007/s00430-002-0175-5. Epub 2003 Mar 5. Med Microbiol Immunol. 2003. PMID: 12684760 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous